Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia.
A dramatic change has occurred in the management of chronic lymphocytic leukemia (CLL) over the past 20 years. The use of newer therapies, including the purine analogues, has resulted in higher frequencies of response. Combination therapy with purine analogues, alkylators, and/or monoclonal antibodies represents a promising new approach to the treatment of patients with CLL. The most commonly studied regimens have utilized fludarabine, but severe myelosuppression and immunosuppression of these combinations require close attention to dosing and schedule. Of the purine analogues that show activity in CLL, pentostatin appears to be the least myelosuppressive. These combination strategies are associated with high-quality responses in the majority of patients and may one day lead to improved survival or possibly even a cure for patients with CLL.
Lamanna
Nicole
N
Department of Medicine, Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Weiss
Mark A
MA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000401:mortality; D015649:Pentostatin / Q000627:therapeutic use; D011684:Purine Nucleosides / Q000627:therapeutic use*; D016879:Salvage Therapy / Q000379:methods
D011684:Purine Nucleosides; D015649:Pentostatin